Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab

Maximillian D.J. Fiander; Virender Bhan; Samuel A. Stewart; Natalie E. Parks

doi:10.1017/cjn.2019.42

Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab

Maximillian D.J. Fiander, Virender Bhan, Samuel A. Stewart, Natalie E. Parks

Medicine

Résultat de recherche: Article › examen par les pairs

1 Citation (Scopus)

Résumé

Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.

Langue d'origine	English
Pages (de-à)	455-458
Nombre de pages	4
Journal	Canadian Journal of Neurological Sciences
Volume	46
Numéro de publication	4
DOI	https://doi.org/10.1017/cjn.2019.42
Statut de publication	Published - juill. 1 2019

Note bibliographique

Publisher Copyright:
© 2019 The Canadian Journal of Neurological Sciences Inc.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

PubMed: MeSH publication types

Journal Article

Accès au document

10.1017/cjn.2019.42

Autres fichiers et liens

Citer

@article{413afa3bf5b148fda8b5dc8cd6b804f0,

title = "Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab",

abstract = "Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.",

author = "Fiander, {Maximillian D.J.} and Virender Bhan and Stewart, {Samuel A.} and Parks, {Natalie E.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Canadian Journal of Neurological Sciences Inc.",

year = "2019",

month = jul,

day = "1",

doi = "10.1017/cjn.2019.42",

language = "English",

volume = "46",

pages = "455--458",

journal = "Canadian Journal of Neurological Sciences",

issn = "0317-1671",

publisher = "Canadian Journal of Neurological Sciences",

number = "4",

}

TY - JOUR

T1 - Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab

AU - Fiander, Maximillian D.J.

AU - Bhan, Virender

AU - Stewart, Samuel A.

AU - Parks, Natalie E.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.

AB - Natalizumab is an efficacious disease modifying therapy (DMT) for relapsing remitting multiple sclerosis (RRMS), often limited by risk of progressive multifocal leukoencephalopathy. We describe the clinical course of RRMS patients switched from natalizumab to another DMT. We identified all RRMS patients treated with natalizumab ≥3 months with JC virus antibody positivity who switched to another DMT. Overall, 84 individuals switched DMT with 57 (68%) beginning fingolimod. On fingolimod, survival without a relapse was 74% (55.8-85.6%) at 36 months and survival without disease progression was 78% (62.6-87.6%) at 36 months. In conclusion, fingolimod is an effective therapy post-natalizumab.

UR - http://www.scopus.com/inward/record.url?scp=85068825219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068825219&partnerID=8YFLogxK

U2 - 10.1017/cjn.2019.42

DO - 10.1017/cjn.2019.42

M3 - Article

C2 - 31113500

AN - SCOPUS:85068825219

SN - 0317-1671

VL - 46

SP - 455

EP - 458

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

IS - 4

ER -

Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer